To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study in Male Subjects With Androgenetic Alopecia to Evaluate the Efficacy, Safety, and Tolerability of KX-826 Following Topical Multiple Dose Administration
In the register
The register attaches this trial to Pyrilutamide (Kintor Pharmaceutical), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Participants (registry)
- 123
- Start
- January 2022
- Primary completion
- February 2023
- Study completion
- February 2023
- Last registry update
- November 2023
- Countries
- United States
Conditions studied: Alopecia, Male Pattern Hair Loss
Interventions: KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, KX-826 dosed at 5mg, Matching placebo to KX-826
Other trials of Pyrilutamide
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
Phase III Study of KX-826 With Adult Male Patients With AGA
To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia
Phase II Study Evaluating the Efficacy and Safety of KX-826
the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending
Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.